logo-loader
viewAcasti Pharma Inc

Acasti Pharma logs three patents in US, Mexico and Japan for flagship drug CaPre

The patents strengthen the IP case for its flagship drug candidate CaPre that treats severe hypertriglyceridemia

Acasti Pharma Inc -
Acasti CEO Jan D’Alvise expects to submit a meeting request for CaPre with the FDA by the close of March

Acasti Pharma Inc (NASDAQ:ACST) (CVE:ACST) has been awarded a notice of allowance for its fourth patent from the US Patent and Trademark office plus a second notice of allowance for its third patent in Mexico. 

These new patents strengthen the intellectual property case for the Canadian biopharma’s flagship drug candidate CaPre, an omega-3 phospholipid that treats severe hypertriglyceridemia, which occurs when triglyceride levels rise.

READ: Acasti Pharma updates on TRILOGY 1 and TRILOGY 2 Phase 3 trials of lead heart drug CaPre

Indeed, the new patents broaden Acasti’s claims for its drug to include any composition containing the two long-chain omega-3 fatty acids – EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid), where at least half of the composition consists of phospholipids, a key class of lipids.

In other news, Acasti is also on the receiving end of a favorable decision by the Japan Patent Office, securing its second patent for CaPre in Japan.

“The United States and Mexico represent important markets for Acasti, given the high prevalence of hypertriglyceridemia and the need for an effective, safe and well-absorbing omega-3 therapeutic for the treatment of cardiovascular-related diseases,” said Dr. Pierre Lemieux, Acasti’s chief operating officer and chief scientific officer in a statement.

“These patents strengthen the company’s strategic position in these important markets, which could support valuable commercial opportunities in the future. In addition, Acasti’s success in upholding its patent in Japan is another confirmation of the strength of our claims and IP portfolio,” he added.

Acasti CEO Jan D’Alvise expects to submit a meeting request for CaPre with the Food and Drug Administration by the close of March. “We look forward to reporting further developments, including an update on a meeting date as soon as it has been set,” D’Alvise said.

Shares added 11.5% in Toronto to C$0.58 each.

---Updates for share price---

Quick facts: Acasti Pharma Inc

Price: 0.87 CAD

TSX-V:ACST
Market: TSX-V
Market Cap: $78.48 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Acasti Pharma Inc named herein, including the promotion by the Company of Acasti Pharma Inc in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Acasti has 'put its finger on something very interesting' in...

Acasti Pharma Inc (NASDAQ:ACST)(CVE:ACST) COO Pierre Lemieux tells Proactive the last patient completed their final visit in its TRILOGY 1 trial of lead drug CaPre, which treats severe hypertriglyceridemia. Lemieux says the Quebec-based company is on its way to reporting results by the end of...

on 11/26/2019

2 min read